Clinical Trial Update: JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)

View source ↗

Summary

Completed post-marketing surveillance study of JARDIANCE (empagliflozin) in Korean patients with chronic kidney disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Jardiance (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Kidney Disease, Chronic | Status: COMPLETED